{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:45:39Z","timestamp":1792226739546,"version":"4.4.0"},"reference-count":198,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T00:00:00Z","timestamp":1550793600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Rheumatol"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1038\/s41584-019-0184-z","type":"journal-article","created":{"date-parts":[[2019,2,22]],"date-time":"2019-02-22T13:03:31Z","timestamp":1550840611000},"page":"208-224","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":129,"title":["Emerging targets of disease-modifying therapy for systemic sclerosis"],"prefix":"10.1038","volume":"15","author":[{"given":"Elizabeth R.","family":"Volkmann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Varga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,2,22]]},"reference":[{"key":"184_CR1","doi-asserted-by":"crossref","first-page":"15002","DOI":"10.1038\/nrdp.2015.2","volume":"1","author":"Y Allanore","year":"2015","unstructured":"Allanore, Y. et al. Systemic sclerosis. Nat. Rev. Dis. Primers 1, 15002 (2015).","journal-title":"Nat. Rev. Dis. Primers"},{"key":"184_CR2","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","volume":"360","author":"A Gabrielli","year":"2009","unstructured":"Gabrielli, A., Avvedimento, E. V. & Krieg, T. Scleroderma. N. Engl. J. Med. 360, 1989\u20132003 (2009).","journal-title":"N. Engl. J. Med."},{"key":"184_CR3","doi-asserted-by":"crossref","first-page":"137","DOI":"10.5301\/jsrd.5000249","volume":"2","author":"J Varga","year":"2017","unstructured":"Varga, J., Trojanowska, M. & Kuwana, M. Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. J. Scleroderma Relat. Disord. 2, 137\u2013152 (2017).","journal-title":"J. Scleroderma Relat. Disord."},{"key":"184_CR4","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1038\/nrd.2016.124","volume":"15","author":"MJ Townsend","year":"2016","unstructured":"Townsend, M. J. & Arron, J. R. Reducing the risk of failure: biomarker-guided trial design. Nat. Rev. Drug Discov. 15, 517\u2013518 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"184_CR5","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-018-04336-z","volume":"9","author":"M Asmani","year":"2018","unstructured":"Asmani, M. et al. Fibrotic microtissue array to predict anti-fibrosis drug efficacy. Nat. Commun. 9, 2066 (2018).","journal-title":"Nat. Commun."},{"key":"184_CR6","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka, O. et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann. Rheum. Dis. 76, 1327\u20131339 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"184_CR7","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","volume":"4","author":"DP Tashkin","year":"2016","unstructured":"Tashkin, D. P. et al. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir. Med. 4, 708\u2013719 (2016).","journal-title":"Lancet Respir. Med."},{"key":"184_CR8","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1002\/art.40560","volume":"70","author":"A Fern\u00e1ndez-Codina","year":"2018","unstructured":"Fern\u00e1ndez-Codina, A., Walker, K. M. & Pope, J. E. Scleroderma Algorithm Group. Treatment algorithms for systemic sclerosis according to experts. Arthritis Rheumatol. 70, 1820\u20131828 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"184_CR9","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI31139","volume":"117","author":"J Varga","year":"2007","unstructured":"Varga, J. & Abraham, D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J. Clin. Invest. 117, 557\u2013567 (2007).","journal-title":"J. Clin. Invest."},{"key":"184_CR10","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrrheum.2011.149","volume":"8","author":"S Bhattacharyya","year":"2011","unstructured":"Bhattacharyya, S., Wei, J. & Varga, J. Understanding fibrosis in systemic sclerosis: shifting paradigms, emerging opportunities. Nat. Rev. Rheumatol. 8, 42\u201354 (2011).","journal-title":"Nat. Rev. Rheumatol."},{"key":"184_CR11","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.ajpath.2012.02.004","volume":"180","author":"B Hinz","year":"2012","unstructured":"Hinz, B. et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am. J. Pathol. 180, 1340\u20131355 (2012).","journal-title":"Am. J. Pathol."},{"key":"184_CR12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.matbio.2018.01.019","volume":"68\u201369","author":"P Pakshir","year":"2018","unstructured":"Pakshir, P. & Hinz, B. The big five in fibrosis: macrophages, myofibroblasts, matrix, mechanics, and miscommunication. Matrix Biol. 68\u201369, 81\u201393 (2018).","journal-title":"Matrix Biol."},{"key":"184_CR13","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11926-018-0710-z","volume":"20","author":"A Santos","year":"2018","unstructured":"Santos, A. & Lagares, D. Matrix stiffness: the conductor of organ fibrosis. Curr. Rheumatol. Rep. 20, 2 (2018).","journal-title":"Curr. Rheumatol. Rep."},{"key":"184_CR14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/nrrheum.2009.26","volume":"5","author":"J Varga","year":"2009","unstructured":"Varga, J. & Pasche, B. Transforming growth factor \u03b2 as a therapeutic target in systemic sclerosis. Nat. Rev. Rheumatol. 5, 200\u2013206 (2009).","journal-title":"Nat. Rev. Rheumatol."},{"key":"184_CR15","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1038\/nrrheum.2014.137","volume":"10","author":"R Lafyatis","year":"2014","unstructured":"Lafyatis, R. Transforming growth factor \u03b2 \u2014 at the centre of systemic sclerosis. Nat. Rev. Rheumatol. 10, 706\u2013719 (2014).","journal-title":"Nat. Rev. Rheumatol."},{"key":"184_CR16","doi-asserted-by":"crossref","first-page":"a022293","DOI":"10.1101\/cshperspect.a022293","volume":"10","author":"KK Kim","year":"2018","unstructured":"Kim, K. K., Sheppard, D. & Chapman, H. A. TGF-\u03b21 signaling and tissue fibrosis. Cold Spring Harb. Perspect. Biol. 10, a022293 (2018).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"184_CR17","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/jid.2009.318","volume":"130","author":"JL Sargent","year":"2010","unstructured":"Sargent, J. L. et al. A TGF\u03b2-responsive gene signature is associated with a subset of diffuse scleroderma with increased disease severity. J. Invest. Dermatol. 130, 694\u2013705 (2010).","journal-title":"J. Invest. Dermatol."},{"key":"184_CR18","doi-asserted-by":"crossref","first-page":"a021907","DOI":"10.1101\/cshperspect.a021907","volume":"8","author":"IB Robertson","year":"2016","unstructured":"Robertson, I. B. & Rifkin, D. B. Regulation of the bioavailability of TGF-\u03b2 and TGF-\u03b2-related proteins. Cold Spring Harb. Perspect. Biol. 8, a021907 (2016).","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"184_CR19","volume":"6","author":"H Xiao","year":"2016","unstructured":"Xiao, H. et al. Metformin is a novel suppressor for transforming growth factor (TGF)-\u03b21. Sci. Rep. 6, 28597 (2016).","journal-title":"Sci. Rep."},{"key":"184_CR20","doi-asserted-by":"crossref","first-page":"C2","DOI":"10.1152\/ajpcell.00060.2014","volume":"307","author":"PS Tsou","year":"2014","unstructured":"Tsou, P. S., Haak, A. J., Khanna, D. & Neubig, R. R. Cellular mechanisms of tissue fibrosis. 8. Current and future drug targets in fibrosis: focus on Rho GTPase-regulated gene transcription. Am. J. Physiol. Cell Physiol. 307, C2\u2013C13 (2014).","journal-title":"Am. J. Physiol. Cell Physiol."},{"key":"184_CR21","doi-asserted-by":"crossref","first-page":"2795","DOI":"10.1172\/JCI77958","volume":"125","author":"LM Rice","year":"2015","unstructured":"Rice, L. M. et al. Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients. J. Clin. Invest. 125, 2795\u20132807 (2015).","journal-title":"J. Clin. Invest."},{"key":"184_CR22","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01371305 (2018)."},{"key":"184_CR23","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1038\/onc.2008.479","volume":"28","author":"S Bhattacharyya","year":"2009","unstructured":"Bhattacharyya, S. et al. A non-SMAD mechanism of fibroblast activation by transforming growth factor-\u03b2 via c-Abl and Egr-1: selective modulation by imatinib mesylate. Oncogene 28, 1285\u20131297 (2009).","journal-title":"Oncogene"},{"key":"184_CR24","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/art.24186","volume":"60","author":"A Akhmetshina","year":"2009","unstructured":"Akhmetshina, A. et al. Treatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosis. Arthritis Rheum. 60, 219\u2013224 (2009).","journal-title":"Arthritis Rheum."},{"key":"184_CR25","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/ard.2010.143974","volume":"70","author":"RF Spiera","year":"2011","unstructured":"Spiera, R. F. et al. Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann. Rheum. Dis. 70, 1003\u20131009 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"184_CR26","doi-asserted-by":"crossref","first-page":"3547","DOI":"10.1002\/art.30549","volume":"63","author":"J Pope","year":"2011","unstructured":"Pope, J. et al. Imatinib in active diffuse cutaneous systemic sclerosis: results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center. Arthritis Rheum. 63, 3547\u20133551 (2011).","journal-title":"Arthritis Rheum."},{"key":"184_CR27","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0187580","volume":"12","author":"V Martyanov","year":"2017","unstructured":"Martyanov, V. et al. Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease. PLOS ONE 12, e0187580 (2017).","journal-title":"PLOS ONE"},{"key":"184_CR28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s13075-015-0721-3","volume":"17","author":"JK Gordon","year":"2015","unstructured":"Gordon, J. K. et al. Nilotinib (Tasigna\u2122) in the treatment of early diffuse systemic sclerosis: an open-label, pilot clinical trial. Arthritis Res. Ther. 17, 213 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"184_CR29","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1136\/annrheumdis-2016-210823","volume":"76","author":"J Huang","year":"2017","unstructured":"Huang, J. et al. Nintedanib inhibits macrophage activation and ameliorates vascular and fibrotic manifestations in the Fra2 mouse model of systemic sclerosis. Ann. Rheum. Dis. 76, 1941\u20131948 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"184_CR30","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02597933 (2018)."},{"key":"184_CR31","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/art.39865","volume":"69","author":"JH Distler","year":"2017","unstructured":"Distler, J. H. et al. Frontiers of antifibrotic therapy in systemic sclerosis. Arthritis Rheumatol. 69, 257\u2013267 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"184_CR32","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03041025 (2018)."},{"key":"184_CR33","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01890265 (2018)."},{"key":"184_CR34","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2353\/ajpath.2009.080574","volume":"174","author":"M Wu","year":"2009","unstructured":"Wu, M. et al. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am. J. Pathol. 174, 519\u2013533 (2009).","journal-title":"Am. J. Pathol."},{"key":"184_CR35","volume":"5","author":"J Wei","year":"2010","unstructured":"Wei, J. et al. PPAR\u03b3 downregulation by TGF\u03b2 in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLOS ONE 5, e13778 (2010).","journal-title":"PLOS ONE"},{"key":"184_CR36","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1186\/s13075-015-0641-2","volume":"17","author":"RG Marangoni","year":"2015","unstructured":"Marangoni, R. G. et al. A candidate gene study reveals association between a variant of the peroxisome proliferator-activated receptor gamma (PPAR-\u03b3) gene and systemic sclerosis. Arthritis Res. Ther. 17, 128 (2015).","journal-title":"Arthritis Res. Ther."},{"key":"184_CR37","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1136\/annrheumdis-2016-210821","volume":"76","author":"J Avouac","year":"2017","unstructured":"Avouac, J. et al. Pan-PPAR agonist IVA337 is effective in experimental lung fibrosis and pulmonary hypertension. Ann. Rheum. Dis. 76, 1931\u20131940 (2017).","journal-title":"Ann. Rheum. Dis."},{"key":"184_CR38","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02503644 (2018)."},{"key":"184_CR39","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/art.30255","volume":"63","author":"GS Bogatkevich","year":"2011","unstructured":"Bogatkevich, G. S. et al. Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease. Arthritis Rheum. 63, 1416\u20131425 (2011).","journal-title":"Arthritis Rheum."},{"key":"184_CR40","doi-asserted-by":"crossref","first-page":"86608","DOI":"10.1172\/jci.insight.86608","volume":"2","author":"BS Shea","year":"2017","unstructured":"Shea, B. S. et al. Uncoupling the profibrotic and hemostatic effects of thrombin in lung fibrosis. JCI Insight 2, 86608 (2017).","journal-title":"JCI Insight"},{"key":"184_CR41","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02426229 (2018)."},{"key":"184_CR42","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1002\/art.39084","volume":"67","author":"T Spadoni","year":"2015","unstructured":"Spadoni, T. et al. A reactive oxygen species-mediated loop maintains increased expression of NADPH oxidases 2 and 4 in skin fibroblasts from patients with systemic sclerosis. Arthritis Rheumatol. 67, 1611\u20131622 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"184_CR43","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1002\/art.39242","volume":"67","author":"S Piera-Velazquez","year":"2015","unstructured":"Piera-Velazquez, S., Makul, A. & Jim\u00e9nez, S. A. Increased expression of NAPDH oxidase 4 in systemic sclerosis dermal fibroblasts: regulation by transforming growth factor \u03b2. Arthritis Rheumatol. 67, 2749\u20132758 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"184_CR44","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nrd4592","volume":"14","author":"CB Nanthakumar","year":"2015","unstructured":"Nanthakumar, C. B. et al. Dissecting fibrosis: therapeutic insights from the small-molecule toolbox. Nat. Rev. Drug Discov. 14, 693\u2013720 (2015).","journal-title":"Nat. Rev. Drug Discov."},{"key":"184_CR45","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.1002\/art.34424","volume":"64","author":"J Wei","year":"2012","unstructured":"Wei, J. et al. Wnt\/\u03b2-catenin signaling is hyperactivated in systemic sclerosis and induces SMAD-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum. 64, 2734\u20132745 (2012).","journal-title":"Arthritis Rheum."},{"key":"184_CR46","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1136\/annrheumdis-2012-202544","volume":"72","author":"C Beyer","year":"2013","unstructured":"Beyer, C. et al. Blockade of canonical Wnt signalling ameliorates experimental dermal fibrosis. Ann. Rheum. Dis. 72, 1255\u20131258 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"184_CR47","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1016\/j.jid.2017.06.032","volume":"137","author":"R Lafyatis","year":"2017","unstructured":"Lafyatis, R. et al. Inhibition of \u03b2-catenin signaling in the skin rescues cutaneous adipogenesis in systemic sclerosis: a randomized, double-blind, placebo-controlled trial of C-82. J. Invest. Dermatol. 137, 2473\u20132483 (2017).","journal-title":"J. Invest. Dermatol."},{"key":"184_CR48","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1002\/art.34444","volume":"64","author":"A Horn","year":"2012","unstructured":"Horn, A. et al. Hedgehog signaling controls fibroblast activation and tissue fibrosis in systemic sclerosis. Arthritis Rheum. 64, 2724\u20132733 (2012).","journal-title":"Arthritis Rheum."},{"key":"184_CR49","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1096\/fj.201600892RR","volume":"31","author":"M Didiasova","year":"2017","unstructured":"Didiasova, M. et al. Pirfenidone exerts antifibrotic effects through inhibition of GLI transcription factors. FASEB J. 31, 1916\u20131928 (2017).","journal-title":"FASEB J."},{"key":"184_CR50","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/1756-185X.13247","volume":"21","author":"H Xiao","year":"2018","unstructured":"Xiao, H. et al. Anti-fibrotic effects of pirfenidone by interference with the Hedgehog signaling pathway in patients with systemic sclerosis-associated interstitial lung disease. Int. J. Rheum. Dis. 21, 477\u2013486 (2018).","journal-title":"Int. J. Rheum. Dis."},{"key":"184_CR51","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.3899\/jrheum.151322","volume":"43","author":"D Khanna","year":"2016","unstructured":"Khanna, D. et al. An open-label, phase II study of the safety and tolerability of pirfenidone in patients with scleroderma-associated interstitial lung disease: the LOTUSS Trial. J. Rheumatol. 43, 1672\u20131679 (2016).","journal-title":"J. Rheumatol."},{"key":"184_CR52","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03221257 (2018)."},{"key":"184_CR53","doi-asserted-by":"crossref","first-page":"R157","DOI":"10.1186\/ar4672","volume":"16","author":"L Desallais","year":"2014","unstructured":"Desallais, L. et al. Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis. Arthritis Res. Ther. 16, R157 (2014).","journal-title":"Arthritis Res. Ther."},{"key":"184_CR54","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ajpath.2011.09.013","volume":"180","author":"S Kitaba","year":"2012","unstructured":"Kitaba, S. et al. Blockade of interleukin-6 receptor alleviates disease in mouse model of scleroderma. Am. J. Pathol. 180, 165\u2013176 (2012).","journal-title":"Am. J. Pathol."},{"key":"184_CR55","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","volume":"387","author":"D Khanna","year":"2016","unstructured":"Khanna, D. et al. Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. Lancet 387, 2630\u20132640 (2016).","journal-title":"Lancet"},{"key":"184_CR56","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","volume":"77","author":"D Khanna","year":"2018","unstructured":"Khanna, D. et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). Ann. Rheum. Dis. 77, 212\u2013220 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"184_CR57","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1136\/annrheumdis-2018-213031","volume":"77","author":"CP Denton","year":"2018","unstructured":"Denton, C. P. et al. Therapeutic interleukin-6 blockade reverses transforming growth factor-\u03b2 pathway activation in dermal fibroblasts: insights from the faSScinate clinical trial in systemic sclerosis. Ann.\u00a0Rheum. Dis. 77, 1362\u20131371 (2018).","journal-title":"Ann. Rheum. Dis."},{"key":"184_CR58","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.cyto.2011.08.030","volume":"56","author":"P Fuschiotti","year":"2011","unstructured":"Fuschiotti, P. Role of IL-13 in systemic sclerosis. Cytokine 56, 544\u2013549 (2011).","journal-title":"Cytokine"},{"key":"184_CR59","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1002\/art.40547","volume":"70","author":"Y Allanore","year":"2018","unstructured":"Allanore, Y. et al. Double-blind, randomized, 8-week placebo-controlled followed by a 16-week open label extension study, with the LPA1 receptor antagonist SAR100842 for patients with diffuse cutaneous systemic sclerosis. Arthritis Rheumatol. 70, 1634\u20131643 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"184_CR60","doi-asserted-by":"crossref","first-page":"3682","DOI":"10.1096\/fj.201600646R","volume":"30","author":"RB Zurier","year":"2016","unstructured":"Zurier, R. B. & Burstein, S. H. Cannabinoids, inflammation, and fibrosis. FASEB J. 30, 3682\u20133689 (2016).","journal-title":"FASEB J."},{"key":"184_CR61","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1136\/annrheumdis-2011-200314","volume":"71","author":"EG Gonzalez","year":"2012","unstructured":"Gonzalez, E. G. et al. Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis. Ann. Rheum. Dis. 71, 1545\u20131551 (2012).","journal-title":"Ann. Rheum. Dis."},{"key":"184_CR62","volume":"6","author":"C R\u00edo del","year":"2016","unstructured":"del R\u00edo, C. et al. The cannabinoid quinol VCE-004.8 alleviates bleomycin-induced scleroderma and exerts potent antifibrotic effects through peroxisome proliferator-activated receptor-\u03b3 and CB2 pathways. Sci. Rep. 6, 21703 (2016).","journal-title":"Sci. Rep."},{"key":"184_CR63","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02465437 (2018)."},{"key":"184_CR64","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03398837 (2019)."},{"key":"184_CR65","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/s41584-018-0025-5","volume":"14","author":"D Katz-Talmor","year":"2018","unstructured":"Katz-Talmor, D. et al. Cannabinoids for the treatment of rheumatic diseases \u2014 where do we stand? Nat.\u00a0Rev. Rheumatol. 14, 488\u2013498 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"184_CR66","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.imlet.2017.09.001","volume":"195","author":"S O\u2019Reilly","year":"2018","unstructured":"O\u2019Reilly, S. Toll like receptors in systemic sclerosis: an emerging target. Immunol. Lett. 195, 2\u20138 (2018).","journal-title":"Immunol. Lett."},{"key":"184_CR67","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ajpath.2012.09.007","volume":"182","author":"S Bhattacharyya","year":"2013","unstructured":"Bhattacharyya, S. et al. Toll-like receptor 4 signaling augments transforming growth factor-\u03b2 responses: a novel mechanism for maintaining and amplifying fibrosis in scleroderma. Am. J. Pathol. 182, 192\u2013205 (2013).","journal-title":"Am. J. Pathol."},{"key":"184_CR68","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.imlet.2017.09.011","volume":"195","author":"S Bhattacharyya","year":"2018","unstructured":"Bhattacharyya, S. & Varga, J. Endogenous ligands of TLR4 promote unresolving tissue fibrosis: implications for systemic sclerosis and its targeted therapy. Immunol. Lett. 195, 9\u201317 (2018).","journal-title":"Immunol. Lett."},{"key":"184_CR69","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1136\/annrheumdis-2012-203095","volume":"73","author":"M Tomcik","year":"2014","unstructured":"Tomcik, M. et al. Heat shock protein 90 (Hsp90) inhibition targets canonical TGF-\u03b2 signalling to prevent fibrosis. Ann. Rheum. Dis. 73, 1215\u20131222 (2014).","journal-title":"Ann. Rheum. Dis."},{"key":"184_CR70","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/art.38901","volume":"67","author":"T Takahashi","year":"2015","unstructured":"Takahashi, T. et al. Amelioration of tissue fibrosis by Toll-like receptor 4 knockout in murine models of systemic sclerosis. Arthritis Rheumatol. 67, 254\u2013265 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"184_CR71","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1002\/art.38288","volume":"66","author":"RB Christmann","year":"2014","unstructured":"Christmann, R. B. et al. Association of interferon- and transforming growth factor \u03b2-regulated genes and macrophage activation with systemic sclerosis-related progressive lung fibrosis. Arthritis Rheumatol. 66, 714\u2013725 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"184_CR72","doi-asserted-by":"crossref","first-page":"57ra82","DOI":"10.1126\/scitranslmed.3001510","volume":"2","author":"G Trujillo","year":"2010","unstructured":"Trujillo, G. et al. TLR9 differentiates rapidly from slowly progressing forms of idiopathic pulmonary fibrosis. Sci. Transl Med. 2, 57ra82 (2010).","journal-title":"Sci. Transl Med."},{"key":"184_CR73","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.ajpath.2014.12.011","volume":"185","author":"V Kirillov","year":"2015","unstructured":"Kirillov, V. et al. Sustained activation of Toll-like receptor 9 induces an invasive phenotype in lung fibroblasts: possible implications in idiopathic pulmonary fibrosis. Am. J. Pathol. 185, 943\u2013957 (2015).","journal-title":"Am. J. Pathol."},{"key":"184_CR74","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1002\/art.39655","volume":"68","author":"F Fang","year":"2016","unstructured":"Fang, F. et al. Toll-like receptor 9 signaling is augmented in systemic sclerosis and elicits transforming growth factor \u03b2-dependent fibroblast activation. Arthritis Rheumatol. 68, 1989\u20132002 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"184_CR75","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s10067-017-3880-6","volume":"37","author":"TA Gheita","year":"2018","unstructured":"Gheita, T. A. et al. Toll-like receptor 9 in systemic sclerosis patients: relation to modified Rodnan skin\u00a0score, disease severity, and functional status. Clin.\u00a0Rheumatol. 37, 757\u2013763 (2018).","journal-title":"Clin. Rheumatol."},{"key":"184_CR76","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.imlet.2017.11.003","volume":"195","author":"AJ Affandi","year":"2018","unstructured":"Affandi, A. J., Carvalheiro, T., Radstake, T. R. D. J. & Marut, W. Dendritic cells in systemic sclerosis: advances from human and mice studies. Immunol. Lett. 195, 18\u201329 (2018).","journal-title":"Immunol. Lett."},{"key":"184_CR77","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa1114576","volume":"370","author":"L Bon Van","year":"2014","unstructured":"Van Bon, L. et al. Proteome-wide analysis and CXCL4 as a biomarker in systemic sclerosis. N. Engl. J. Med. 370, 433\u2013443 (2014).","journal-title":"N. Engl. J. Med."},{"key":"184_CR78","doi-asserted-by":"crossref","first-page":"44","DOI":"10.4049\/jimmunol.1002218","volume":"186","author":"AA Divekar","year":"2011","unstructured":"Divekar, A. A. et al. pDCs and IL-4+ T cells in scleroderma as novel targets of imatinib mesylate. J. Immunol. 186, 44 (2011).","journal-title":"J. Immunol."},{"key":"184_CR79","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.98380","volume":"3","author":"S Kafaja","year":"2018","unstructured":"Kafaja, S. et al. pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis. JCI Insight 3, e98380 (2018).","journal-title":"JCI Insight"},{"key":"184_CR80","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1002\/art.40163","volume":"69","author":"M Rossato","year":"2017","unstructured":"Rossato, M. et al. Association of microRNA-618 expression with altered frequency and activation of plasmacytoid dendritic cells in patients with systemic sclerosis. Arthritis Rheumatol. 69, 1891\u20131902 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"184_CR81","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1517\/14728222.2012.708339","volume":"16","author":"WJ Peng","year":"2012","unstructured":"Peng, W. J. MicroRNA-29: a potential therapeutic target for systemic sclerosis. Expert Opin. Ther. Targets 16, 875\u2013879 (2012).","journal-title":"Expert Opin. Ther. Targets"},{"key":"184_CR82","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.immuni.2016.02.015","volume":"44","author":"TA Wynn","year":"2016","unstructured":"Wynn, T. A. & Vanella, K. M. Macrophages in tissue repair, regeneration, and fibrosis. Immunity 44, 450\u2013462 (2016).","journal-title":"Immunity"},{"key":"184_CR83","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02550873 (2018)."},{"key":"184_CR84","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.imlet.2017.12.001","volume":"195","author":"J King","year":"2018","unstructured":"King, J., Abraham, D. & Stratton, R. Chemokines in systemic sclerosis. Immunol. Lett. 195, 68\u201375 (2018).","journal-title":"Immunol. Lett."},{"key":"184_CR85","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1586\/1744666X.2013.848792","volume":"9","author":"FV Castelino","year":"2013","unstructured":"Castelino, F. V. & Varga, J. Current status of systemic sclerosis biomarkers: applications for diagnosis, management and drug development. Expert Rev. Clin.\u00a0Immunol. 9, 1077\u20131090 (2013).","journal-title":"Expert Rev. Clin. Immunol."},{"key":"184_CR86","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/s41584-018-0021-9","volume":"14","author":"P Wermuth","year":"2018","unstructured":"Wermuth, P., Piera-Velazquez, S., Rosenbloom, J. & Jimenez, S. A. Existing and novel biomarkers for precision medicine in systemic sclerosis. Nat. Rev. Rheumatol. 14, 421\u2013432 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"184_CR87","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/sj.jid.5700302","volume":"126","author":"AM Ferreira","year":"2006","unstructured":"Ferreira, A. M. et al. Diminished induction of skin fibrosis in mice with MCP-1 deficiency. J. Invest. Dermatol. 126, 1900\u20131908 (2006).","journal-title":"J. Invest. Dermatol."},{"key":"184_CR88","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/1529-0131(200111)44:11<2665::AID-ART446>3.0.CO;2-S","volume":"44","author":"O Distler","year":"2001","unstructured":"Distler, O. et al. Overexpression of monocyte chemoattractant protein 1 in systemic sclerosis: role of platelet-derived growth factor and effects on monocyte chemotaxis and collagen synthesis. Arthritis Rheum. 44, 2665\u20132678 (2001).","journal-title":"Arthritis Rheum."},{"key":"184_CR89","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1093\/rheumatology\/kem313","volume":"47","author":"A Antonelli","year":"2008","unstructured":"Antonelli, A. et al. CXCL10 (\u03b1) and CCL2 (\u03b2) chemokines in systemic sclerosis \u2014 a longitudinal study. Rheumatology 47, 45\u201349 (2008).","journal-title":"Rheumatology"},{"key":"184_CR90","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1136\/ard.2006.067967","volume":"67","author":"MT Carulli","year":"2008","unstructured":"Carulli, M. T. et al. Can CCL2 serum levels be used in risk stratification or to monitor treatment response in systemic sclerosis? Ann. Rheum. Dis. 67, 105\u2013109 (2008).","journal-title":"Ann. Rheum. Dis."},{"key":"184_CR91","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1002\/art.40171","volume":"69","author":"M Wu","year":"2017","unstructured":"Wu, M. et al. CCL2 in the circulation predicts long-term progression of interstitial lung disease in patients with early systemic sclerosis: data from two independent cohorts. Arthritis Rheumatol. 69, 1871\u20131878 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"184_CR92","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/art.37742","volume":"65","author":"X Liu","year":"2013","unstructured":"Liu, X. et al. Correlation of interferon-inducible chemokine plasma levels with disease severity in systemic sclerosis. Arthritis Rheum. 65, 226\u2013235 (2013).","journal-title":"Arthritis Rheum."},{"key":"184_CR93","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s13075-016-1203-y","volume":"18","author":"ER Volkmann","year":"2016","unstructured":"Volkmann, E. R. et al. Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung disease. Arthritis Res. Ther. 18, 305 (2016).","journal-title":"Arthritis Res. Ther."},{"key":"184_CR94","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0184694","volume":"12","author":"T Puengel","year":"2017","unstructured":"Puengel, T. et al. Differential impact of the dual CCR2\/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury. PLOS ONE 12, e0184694 (2017).","journal-title":"PLOS ONE"},{"key":"184_CR95","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1002\/art.21975","volume":"54","author":"JJ Haringman","year":"2006","unstructured":"Haringman, J. J. et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. Arthritis Rheum. 54, 2387\u20132392 (2006).","journal-title":"Arthritis Rheum."},{"key":"184_CR96","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/art.23591","volume":"58","author":"CE Vergunst","year":"2008","unstructured":"Vergunst, C. E. et al. Modulation of CCR2 in rheumatoid arthritis: a double-blind, randomized, placebo-controlled clinical trial. Arthritis Rheum. 58, 1931\u20131939 (2008).","journal-title":"Arthritis Rheum."},{"key":"184_CR97","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1136\/annrheumdis-2011-201605","volume":"72","author":"PP Tak","year":"2013","unstructured":"Tak, P. P. et al. Chemokine receptor CCR1 antagonist CCX354-C treatment for rheumatoid arthritis: CARAT-2, a randomised, placebo controlled clinical trial. Ann. Rheum. Dis. 72, 337\u2013344 (2013).","journal-title":"Ann. Rheum. Dis."},{"key":"184_CR98","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/JLB.5RI0218-084R","volume":"104","author":"M Gadina","year":"2018","unstructured":"Gadina, M. et al. Translational and clinical advances in JAK\u2013STAT biology: the present and future of jakinibs. J. Leukoc. Biol. 104, 499\u2013514 (2018).","journal-title":"J. Leukoc. Biol."},{"key":"184_CR99","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1038\/ni.3691","volume":"18","author":"AV Villarino","year":"2017","unstructured":"Villarino, A. V., Kanno, Y. & O\u2019Shea, J. J. Mechanisms and consequences of JAK\u2013STAT signaling in the immune system. Nat. Immunol. 18, 374\u2013384 (2017).","journal-title":"Nat. Immunol."},{"key":"184_CR100","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrrheum.2018.31","volume":"14","author":"TLW Muskardin","year":"2018","unstructured":"Muskardin, T. L. W. & Niewold, T. B. Type I interferon in rheumatic diseases. Nat. Rev. Rheumatol. 14, 214\u2013228 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"184_CR101","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1080\/14656566.2017.1378343","volume":"18","author":"L Costa","year":"2017","unstructured":"Costa, L. et al. Small molecule therapy for managing moderate to severe psoriatic arthritis. Expert Opin. Pharmacother. 18, 1557\u20131567 (2017).","journal-title":"Expert Opin. Pharmacother."},{"key":"184_CR102","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/2040622317743486","volume":"9","author":"S Dubash","year":"2018","unstructured":"Dubash, S., McGonagle, D. & Marzo-Ortega, H. New advances in the understanding and treatment of\u00a0axial spondyloarthritis: from chance to choice. Ther.\u00a0Adv. Chronic Dis. 9, 77\u201387 (2018).","journal-title":"Ther. Adv. Chronic Dis."},{"key":"184_CR103","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1111\/apt.14669","volume":"47","author":"JR White","year":"2018","unstructured":"White, J. R. et al. Review article: novel oral-targeted therapies in inflammatory bowel disease. Aliment. Pharmacol. Ther. 47, 1610\u20131622 (2018).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"184_CR104","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/ijd.14064","volume":"57","author":"JS Kahn","year":"2018","unstructured":"Kahn, J. S., Deverapalli, S. C. & Rosmarin, D. M. JAK\u2013STAT signaling pathway inhibition: a role for treatment of discoid lupus erythematosus and dermatomyositis. Int. J. Dermatol. 57, 1007\u20131014 (2018).","journal-title":"Int. J. Dermatol."},{"key":"184_CR105","doi-asserted-by":"crossref","first-page":"3006","DOI":"10.1002\/art.34500","volume":"64","author":"C Dees","year":"2012","unstructured":"Dees, C. et al. JAK-2 as a novel mediator of the profibrotic effects of transforming growth factor \u03b2 in systemic sclerosis. Arthritis Rheum. 64, 3006\u20133015 (2012).","journal-title":"Arthritis Rheum."},{"key":"184_CR106","volume":"8","author":"D Chakraborty","year":"2017","unstructured":"Chakraborty, D., \u0160umov\u00e1, B. & Mallano, T. Activation of STAT3 integrates common profibrotic pathways to promote fibroblast activation and tissue fibrosis. Nat.\u00a0Commun. 8, 1130 (2017).","journal-title":"Nat. Commun."},{"key":"184_CR107","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1111\/ijd.12839","volume":"55","author":"Y Xu","year":"2016","unstructured":"Xu, Y. et al. Polymorphisms in STAT4 and IRF5 increase the risk of systemic sclerosis: a meta-analysis. Int. J. Dermatol. 55, 408\u2013416 (2016).","journal-title":"Int. J. Dermatol."},{"key":"184_CR108","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1002\/art.24688","volume":"60","author":"P Dieud\u00e9","year":"2009","unstructured":"Dieud\u00e9, P. et al. STAT4 is a genetic risk factor for systemic sclerosis having additive effects with IRF5 on disease susceptibility and related pulmonary fibrosis. Arthritis Rheum. 60, 2472\u20132479 (2009).","journal-title":"Arthritis Rheum."},{"key":"184_CR109","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03274076 (2018)."},{"key":"184_CR110","doi-asserted-by":"crossref","DOI":"10.1111\/jdv.14876","volume":"32","author":"SC Deverapalli","year":"2018","unstructured":"Deverapalli, S. C. & Rosmarin, D. The use of JAK inhibitors in the treatment of progressive systemic sclerosis. J. Eur. Acad. Dermatol. Venereol. 32, e328 (2018).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"184_CR111","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/art.38219","volume":"66","author":"V Sobanski","year":"2014","unstructured":"Sobanski, V. et al. Prevalence of anti-RNA polymerase III antibodies in systemic sclerosis: new data from a French cohort and a systematic review and meta-analysis. Arthritis Rheumatol. 66, 407\u2013417 (2014).","journal-title":"Arthritis Rheumatol."},{"key":"184_CR112","first-page":"389","volume":"2","author":"MD Kraaij","year":"2008","unstructured":"Kraaij, M. D. & van Laar, J. M. The role of B cells in systemic sclerosis. Biologics 2, 389\u2013395 (2008).","journal-title":"Biologics"},{"key":"184_CR113","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1002\/art.23806","volume":"58","author":"M Manetti","year":"2008","unstructured":"Manetti, M. et al. Endothelial\/lymphocyte activation leads to prominent CD4+T cell infiltration in the gastric mucosa of patients with systemic sclerosis. Arthritis Rheum. 58, 2866\u20132873 (2008).","journal-title":"Arthritis Rheum."},{"key":"184_CR114","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1002\/art.22847","volume":"56","author":"R Lafyatis","year":"2007","unstructured":"Lafyatis, R., O\u2019Hara, C., Feghali-Bostwick, C. A. & Matteson, E. B cell infiltration in systemic sclerosis-associated interstitial lung disease. Arthritis Rheum. 56, 3167\u20133168 (2007).","journal-title":"Arthritis Rheum."},{"key":"184_CR115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1752-699X.2010.00228.x","volume":"6","author":"M Santis De","year":"2012","unstructured":"De Santis, M. et al. Bronchoalveolar lavage fluid and progression of scleroderma interstitial lung disease. Clin. Respir. J. 6, 9\u201317 (2012).","journal-title":"Clin. Respir. J."},{"key":"184_CR116","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1136\/annrheumdis-2013-204522","volume":"74","author":"S Jordan","year":"2015","unstructured":"Jordan, S. et al. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group. Ann.\u00a0Rheum. Dis. 74, 1188\u20131194 (2015).","journal-title":"Ann. Rheum. Dis."},{"key":"184_CR117","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/art.20274","volume":"50","author":"S Sato","year":"2004","unstructured":"Sato, S., Fujimoto, M., Hasegawa, M. & Takehara, K. Altered blood B lymphocyte homeostasis in systemic sclerosis: expanded naive B cells and diminished but activated memory B cells. Arthritis Rheum. 50, 1918\u20131927 (2004).","journal-title":"Arthritis Rheum."},{"key":"184_CR118","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/2047-783X-15-1-44","volume":"15","author":"T Gambichler","year":"2010","unstructured":"Gambichler, T. et al. Absolute count of T and B\u00a0lymphocyte subsets is decreased in systemic sclerosis. Eur. J. Med. Res. 15, 44\u201346 (2010).","journal-title":"Eur. J. Med. Res."},{"key":"184_CR119","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.revmed.2016.02.016","volume":"38","author":"S Sanges","year":"2017","unstructured":"Sanges, S. et al. Role of B cells in the pathogenesis of systemic sclerosis. Rev. Med. Interne 38, 113\u2013124 (2017).","journal-title":"Rev. Med. Interne"},{"key":"184_CR120","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1002\/art.39437","volume":"68","author":"A Mavropoulos","year":"2016","unstructured":"Mavropoulos, A. et al. Breg cells are numerically decreased and functionally impaired in patients with systemic sclerosis. Arthritis Rheumatol. 68, 494\u2013504 (2016).","journal-title":"Arthritis Rheumatol."},{"key":"184_CR121","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1093\/rheumatology\/kev331","volume":"55","author":"T Matsushita","year":"2016","unstructured":"Matsushita, T. et al. Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity. Rheumatology 55, 263\u2013267 (2016).","journal-title":"Rheumatology"},{"key":"184_CR122","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0002-9440(10)63328-7","volume":"165","author":"N Asano","year":"2004","unstructured":"Asano, N. et al. B Lymphocyte signaling established by the CD19\/CD22 loop regulates autoimmunity in the tight-skin mouse. Am. J. Pathol. 165, 641\u2013650 (2004).","journal-title":"Am. J. Pathol."},{"key":"184_CR123","doi-asserted-by":"crossref","first-page":"496","DOI":"10.3389\/fimmu.2015.00496","volume":"6","author":"L Soto","year":"2015","unstructured":"Soto, L. et al. Systemic sclerosis patients present alterations in the expression of molecules involved in B cell regulation. Front. Immunol. 6, 496 (2015).","journal-title":"Front. Immunol."},{"key":"184_CR124","doi-asserted-by":"crossref","first-page":"6635","DOI":"10.4049\/jimmunol.165.11.6635","volume":"165","author":"S Sato","year":"2000","unstructured":"Sato, S. et al. Quantitative genetic variation in CD19 expression correlates with autoimmunity. J. Immunol. 165, 6635\u20136643 (2000).","journal-title":"J. Immunol."},{"key":"184_CR125","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1136\/annrheumdis-2015-207392","volume":"75","author":"Z Brkic","year":"2016","unstructured":"Brkic, Z. et al. The interferon type I signature is present in systemic sclerosis before overt fibrosis and might contribute to its pathogenesis through high BAFF gene expression and high collagen synthesis. Ann. Rheum. Dis. 75, 1567\u20131573 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"184_CR126","first-page":"2056","volume":"34","author":"T Matsushita","year":"2007","unstructured":"Matsushita, T. et al. Elevated serum APRIL levels in patients with systemic sclerosis: distinct profiles of systemic sclerosis categorized by APRIL and BAFF. J. Rheumatol. 34, 2056\u20132062 (2007).","journal-title":"J. Rheumatol."},{"key":"184_CR127","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.3899\/jrheum.100454","volume":"37","author":"M Bielecki","year":"2010","unstructured":"Bielecki, M. et al. Increased production of a proliferation-inducing ligand (APRIL) by peripheral blood mononuclear cells is associated with anti-topoisomerase I antibody and more severe disease in systemic sclerosis. J. Rheumatol. 37, 2286\u20132289 (2010).","journal-title":"J. Rheumatol."},{"key":"184_CR128","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1182\/blood.V97.1.198","volume":"97","author":"B Nardelli","year":"2001","unstructured":"Nardelli, B. et al. Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97,\u00a0198\u2013204 (2001).","journal-title":"Blood"},{"key":"184_CR129","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1002\/art.21526","volume":"54","author":"T Matsushita","year":"2006","unstructured":"Matsushita, T. et al. Elevated serum BAFF levels in patients with systemic sclerosis: enhanced BAFF signaling in systemic sclerosis B lymphocytes. Arthritis Rheum. 54, 192\u2013201 (2006).","journal-title":"Arthritis Rheum."},{"key":"184_CR130","doi-asserted-by":"crossref","first-page":"eaas9944","DOI":"10.1126\/sciadv.aas9944","volume":"4","author":"T Matsushita","year":"2018","unstructured":"Matsushita, T. et al. BAFF inhibition attenuates fibrosis in scleroderma by modulating the regulatory and effector B cell balance. Sci. Adv. 4, eaas9944 (2018).","journal-title":"Sci. Adv."},{"key":"184_CR131","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.jbspin.2010.05.004","volume":"78","author":"H Bassyouni","year":"2011","unstructured":"Bassyouni, H. et al. Elevated serum levels of a proliferation-inducing ligand in patients with systemic sclerosis: possible association with myositis? Joint\u00a0Bone Spine 78, 56\u201361 (2011).","journal-title":"Joint Bone Spine"},{"key":"184_CR132","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.autrev.2017.12.010","volume":"17","author":"M Thiebaut","year":"2018","unstructured":"Thiebaut, M. et al. Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review. Autoimmun. Rev. 17, 582\u2013587 (2018).","journal-title":"Autoimmun. Rev."},{"key":"184_CR133","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.semarthrit.2016.10.003","volume":"46","author":"D Daoussis","year":"2017","unstructured":"Daoussis, D. et al. A multicenter, open-label, comparative study of B cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease. Semin. Arthritis Rheum. 46, 625\u2013631 (2017).","journal-title":"Semin. Arthritis Rheum."},{"key":"184_CR134","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1002\/art.40656","volume":"70","author":"K Streicher","year":"2018","unstructured":"Streicher, K. et al. Baseline plasma cell gene signature predicts improvement in systemic sclerosis skin scores following treatment with inebilizumab (MEDI-551) and correlates with disease activity in systemic lupus erythematosus and chronic obstructive pulmonary disease. Arthritis Rheumatol. 70, 2087\u20132095 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"184_CR135","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1002\/art.40358","volume":"70","author":"JK Gordon","year":"2018","unstructured":"Gordon, J. K. et al. Belimumab for the treatment of early diffuse systemic sclerosis: results of a randomized, double-blind, placebo-controlled, pilot trial. Arthritis Rheumatol. 70, 308\u2013316 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"184_CR136","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1684\/ecn.2013.0325","volume":"23","author":"NC Brembilla","year":"2012","unstructured":"Brembilla, N. C. & Chizzolini, C. T cell abnormalities in\u00a0systemic sclerosis with a focus on TH17 cells. Eur.\u00a0Cytokine Netw. 23, 128\u2013139 (2012).","journal-title":"Eur. Cytokine Netw."},{"key":"184_CR137","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1093\/rheumatology\/kes090","volume":"51","author":"S O\u2019Reilly","year":"2012","unstructured":"O\u2019Reilly, S., Hugle, T. & van Laar, J. M. T cells in systemic sclerosis: a reappraisal. Rheumatology 51, 1540\u20131549 (2012).","journal-title":"Rheumatology"},{"key":"184_CR138","doi-asserted-by":"crossref","first-page":"R166","DOI":"10.1186\/ar3486","volume":"13","author":"ME Truchetet","year":"2011","unstructured":"Truchetet, M. E. Increased frequency of circulating TH22 in addition to TH17 and TH2 lymphocytes in systemic sclerosis: association with interstitial lung disease. Arthritis Res. Ther. 13, R166 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"184_CR139","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1007\/s00296-011-2056-y","volume":"32","author":"TS Rodriguez-Reyna","year":"2012","unstructured":"Rodriguez-Reyna, T. S. et al. TH17 peripheral cells are increased in diffuse cutaneous systemic sclerosis compared with limited illness: a cross-sectional study. Rheumatol. Int. 32, 2653\u20132660 (2012).","journal-title":"Rheumatol. Int."},{"key":"184_CR140","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/nri3605","volume":"14","author":"A Liston","year":"2014","unstructured":"Liston, A. & Gray, D. H. Homeostatic control of regulatory T cell diversity. Nat. Rev. Immunol. 14, 154\u2013165 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"184_CR141","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1038\/nri2889","volume":"10","author":"JH Buckner","year":"2010","unstructured":"Buckner, J. H. Mechanisms of impaired regulation by CD4+CD25+FOXP3+ regulatory T cells in human autoimmune diseases. Nat. Rev. Immunol. 10, 849\u2013859 (2010).","journal-title":"Nat. Rev. Immunol."},{"key":"184_CR142","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.jaci.2014.12.1932","volume":"135","author":"KG MacDonald","year":"2015","unstructured":"MacDonald, K. G. et al. Regulatory T cells produce profibrotic cytokines in the skin of patients with systemic sclerosis. J. Allergy Clin. Immunol. 135, 946 (2015).","journal-title":"J. Allergy Clin. Immunol."},{"key":"184_CR143","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s12016-016-8563-6","volume":"52","author":"G Slobodin","year":"2017","unstructured":"Slobodin, G. & Rimar, D. Regulatory T cells in systemic sclerosis: a comprehensive review. Clin. Rev. Allergy Immunol. 52, 194\u2013201 (2017).","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"184_CR144","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.cellimm.2009.12.009","volume":"261","author":"G Slobodin","year":"2010","unstructured":"Slobodin, G. et al. Regulatory T cells (CD4+CD25brightFoxP3+) expansion in systemic sclerosis correlates with disease activity and severity. Cell. Immunol. 261, 77\u201380 (2010).","journal-title":"Cell. Immunol."},{"key":"184_CR145","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.3760\/cma.j.issn.0366-6999.20141395","volume":"127","author":"N Jiang","year":"2014","unstructured":"Jiang, N., Li, M. & Zeng, X. Correlation of TH17 cells and CD4+CD25+ regulatory T cells with clinical parameters in patients with systemic sclerosis. Chin.\u00a0Med. J. 127, 3557\u20133561 (2014).","journal-title":"Chin. Med. J."},{"key":"184_CR146","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1136\/ard.2010.137935","volume":"70","author":"MO Becker","year":"2011","unstructured":"Becker, M. O. et al. The monoclonal anti-CD25 antibody basiliximab for the treatment of progressive systemic sclerosis: an open-label study. Ann. Rheum. Dis. 70, 1340\u20131341 (2011).","journal-title":"Ann. Rheum. Dis."},{"key":"184_CR147","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1136\/annrheumdis-2015-208213","volume":"75","author":"M Ponsoye","year":"2016","unstructured":"Ponsoye, M. et al. Treatment with abatacept prevents experimental dermal fibrosis and induces regression of established inflammation-driven fibrosis. Ann. Rheum. Dis. 75, 2142\u20132149 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"184_CR148","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1136\/annrheumdis-2012-202657","volume":"72","author":"M Elhai","year":"2013","unstructured":"Elhai, M. et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann. Rheum. Dis. 72, 1217\u20131220 (2013).","journal-title":"Ann. Rheum. Dis."},{"issue":"Suppl. 10","key":"184_CR149","first-page":"900","volume":"70","author":"D Khanna","year":"2018","unstructured":"Khanna, D. et al. Abatacept versus placebo in early diffuse cutaneous systemic sclerosis \u2014 results of a phase 2 investigator initiated, double-blind, placebo-controlled, multicenter, randomized controlled trial. Arthritis Rheumatol. 70 (Suppl. 10), 900 (2018).","journal-title":"Arthritis Rheumatol."},{"key":"184_CR150","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","volume":"311","author":"JM Laar van","year":"2014","unstructured":"van Laar, J. M. et al. Autologous hematopoietic stem cell transplantation versus intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial. JAMA 311, 2490\u20132498 (2014).","journal-title":"JAMA"},{"key":"184_CR151","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","volume":"378","author":"RK Burt","year":"2011","unstructured":"Burt, R. K. et al. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial. Lancet 378, 498\u2013506 (2011).","journal-title":"Lancet"},{"key":"184_CR152","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","volume":"378","author":"KM Sullivan","year":"2018","unstructured":"Sullivan, K. M. et al. Myeloablative autologous stem-cell transplantation for severe scleroderma. N. Engl. J.\u00a0Med. 378, 35\u201347 (2018).","journal-title":"N. Engl. J. Med."},{"key":"184_CR153","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1007\/s11926-015-0555-7","volume":"18","author":"FC Rhijn-Brouwer van","year":"2016","unstructured":"van Rhijn-Brouwer, F. C. et al. Cellular therapies in systemic sclerosis: recent progress. Curr. Rheumatol. Rep. 18, 12 (2016).","journal-title":"Curr. Rheumatol. Rep."},{"key":"184_CR154","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1016\/j.bbmt.2018.06.025","volume":"24","author":"KM Sullivan","year":"2018","unstructured":"Sullivan, K. M. et al. Systemic sclerosis as an indication for autologous hematopoietic cell transplantation: position statement from the American Society for Blood and Marrow Transplantation. Biol. Blood Marrow Transplant. 24, 1961\u20131964 (2018).","journal-title":"Biol. Blood Marrow Transplant."},{"key":"184_CR155","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1182\/bloodadvances.2017011072","volume":"2","author":"LCM Arruda","year":"2018","unstructured":"Arruda, L. C. M. et al. Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients. Blood Adv. 2, 126\u2013141 (2018).","journal-title":"Blood Adv."},{"key":"184_CR156","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1038\/bmt.2013.202","volume":"49","author":"J Baraut","year":"2014","unstructured":"Baraut, J. et al. Peripheral blood regulatory T cells in patients with diffuse systemic sclerosis (SSc) before and after autologous hematopoietic SCT: a pilot study. Bone Marrow Transplant. 49, 349\u2013354 (2014).","journal-title":"Bone Marrow Transplant."},{"key":"184_CR157","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3109\/03009742.2011.606788","volume":"41","author":"P Szodoray","year":"2012","unstructured":"Szodoray, P. et al. Immunological reconstitution after autologous stem cell transplantation in patients with refractory systemic autoimmune diseases. Scand. J. Rheumatol. 41, 110\u2013115 (2012).","journal-title":"Scand. J. Rheumatol."},{"key":"184_CR158","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/2397198317753468","volume":"3","author":"D Khanna","year":"2018","unstructured":"Khanna, D. et al. Adipose-derived cell therapy for hand dysfunction in patients with systemic sclerosis: a randomized, double-blind, placebo-controlled trial. J. Scleroderma Relat. Disord. 3, 69\u2013101 (2018).","journal-title":"J. Scleroderma Relat. Disord."},{"key":"184_CR159","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1002\/art.37988","volume":"65","author":"M Matucci-Cerinic","year":"2013","unstructured":"Matucci-Cerinic, M. et al. Review: evidence that systemic sclerosis is a vascular disease. Arthritis Rheum. 65, 1953\u20131962 (2013).","journal-title":"Arthritis Rheum."},{"key":"184_CR160","first-page":"175","volume":"36","author":"TM Frech","year":"2018","unstructured":"Frech, T. M. et al. Implications of endothelial shear stress on systemic sclerosis vasculopathy and treatment. Clin. Exp. Rheumatol. 36, 175\u2013182 (2018).","journal-title":"Clin. Exp. Rheumatol."},{"key":"184_CR161","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.3389\/fphys.2018.01177","volume":"9","author":"AE Abdulle","year":"2018","unstructured":"Abdulle, A. E., Diercks, G. F. H., Feelisch, M., Mulder, D. J. & van Goor, H. The role of oxidative stress in the development of systemic sclerosis related vasculopathy. Front. Physiol. 9, 1177 (2018).","journal-title":"Front. Physiol."},{"key":"184_CR162","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3389\/fimmu.2018.02045","volume":"9","author":"C Bruni","year":"2018","unstructured":"Bruni, C. et al. Vascular leaking, a pivotal and early pathogenetic event in systemic sclerosis: should the door be closed? Front. Immunol. 9, 204 (2018).","journal-title":"Front. Immunol."},{"key":"184_CR163","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1183\/09031936.00137511","volume":"40","author":"G Simonneau","year":"2012","unstructured":"Simonneau, G. et al. Selexipag, an oral, selective IP receptor agonist for the treatment of pulmonary arterial hypertension. Eur. Respir. J. 40, 874\u2013880 (2012).","journal-title":"Eur. Respir. J."},{"key":"184_CR164","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13075-018-1577-0","volume":"20","author":"M Cutolo","year":"2018","unstructured":"Cutolo, M. et al. Effects of selexipag and its active metabolite in contrasting the profibrotic myofibroblast activity in cultured scleroderma skin fibroblasts. Arthritis Res. Ther. 20, 77 (2018).","journal-title":"Arthritis Res. Ther."},{"key":"184_CR165","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1002\/art.40242","volume":"69","author":"CP Denton","year":"2017","unstructured":"Denton, C. P. et al. Efficacy and safety of selexipag in adults with Raynaud\u2019s phenomenon secondary to systemic sclerosis: a randomized, placebo-controlled, phase II study. Arthritis Rheumatol. 69, 2370\u20132379 (2017).","journal-title":"Arthritis Rheumatol."},{"key":"184_CR166","doi-asserted-by":"crossref","first-page":"1602493","DOI":"10.1183\/13993003.02493-2016","volume":"50","author":"S Gaine","year":"2017","unstructured":"Gaine, S. et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur. Respir. J. 50, 1602493 (2017).","journal-title":"Eur. Respir. J."},{"key":"184_CR167","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Puliod","year":"2013","unstructured":"Puliod, T. et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N. Engl. J. Med. 369, 809\u2013818 (2013).","journal-title":"N. Engl. J. Med."},{"key":"184_CR168","doi-asserted-by":"crossref","first-page":"1975","DOI":"10.1001\/jama.2016.5258","volume":"315","author":"D Khanna","year":"2016","unstructured":"Khanna, D. et al. Effect of macitentan on the development of new ischemic digital ulcers in patients with systemic sclerosis: DUAL-1 and DUAL-2 randomized clinical trials. JAMA 315, 1975\u20131988 (2016).","journal-title":"JAMA"},{"key":"184_CR169","doi-asserted-by":"crossref","first-page":"530","DOI":"10.3109\/s10165-009-0199-4","volume":"19","author":"M Kuwana","year":"2009","unstructured":"Kuwana, M., Okazaki, Y. & Kaburaki, J. Long-term beneficial effects of statins on vascular manifestations in patients with systemic sclerosis. Mod. Rheumatol. 19, 530\u2013535 (2009).","journal-title":"Mod. Rheumatol."},{"key":"184_CR170","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1136\/ard.2005.046870","volume":"65","author":"S Furukawa","year":"2006","unstructured":"Furukawa, S. et al. Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study. Ann. Rheum. Dis. 65, 1118\u20131120 (2006).","journal-title":"Ann. Rheum. Dis."},{"key":"184_CR171","first-page":"1801","volume":"35","author":"A Abou-Raya","year":"2008","unstructured":"Abou-Raya, A., Abou-Raya, S. & Helmii, M. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud\u2019s phenomenon and digital ulcers. J. Rheumatol. 35, 1801\u20131808 (2008).","journal-title":"J. Rheumatol."},{"key":"184_CR172","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1093\/rheumatology\/keq003","volume":"49","author":"HY Sadik","year":"2010","unstructured":"Sadik, H. Y. et al. Lack of effect of 8 weeks atorvastatin on microvascular endothelial function in patients with systemic sclerosis. Rheumatology 49, 990\u2013996 (2010).","journal-title":"Rheumatology"},{"key":"184_CR173","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02370784 (2018)."},{"key":"184_CR174","doi-asserted-by":"crossref","DOI":"10.1038\/srep41605","volume":"7","author":"AP Grzegorzewska","year":"2017","unstructured":"Grzegorzewska, A. P. et al. Dimethyl fumarate ameliorates pulmonary arterial hypertension and lung fibrosis by targeting multiple pathways. Sci. Rep. 7, 41605 (2017).","journal-title":"Sci. Rep."},{"key":"184_CR175","doi-asserted-by":"crossref","first-page":"3639","DOI":"10.1074\/jbc.M115.679704","volume":"291","author":"I Kastrati","year":"2016","unstructured":"Kastrati, I. et al. Dimethyl fumarate inhibits the nuclear factor \u03baB pathway in breast cancer cells by covalent modification of p65 protein. J. Biol. Chem. 291, 3639\u20133647 (2016).","journal-title":"J. Biol. Chem."},{"key":"184_CR176","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jid.2017.08.024","volume":"138","author":"T Toyama","year":"2018","unstructured":"Toyama, T. et al. Therapeutic targeting of TAZ and YAP by dimethyl fumarate in systemic sclerosis fibrosis. J. Invest. Dermatol. 138, 78\u201388 (2018).","journal-title":"J. Invest. Dermatol."},{"key":"184_CR177","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.trsl.2016.12.002","volume":"183","author":"J Wei","year":"2017","unstructured":"Wei, J. et al. Nrf2 exerts cell-autonomous antifibrotic effects: compromised function in systemic sclerosis and therapeutic rescue with a novel heterocyclic chalcone derivative. Transl Res. 183, 71\u201386 (2017).","journal-title":"Transl. Res."},{"key":"184_CR178","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02981082 (2018)."},{"key":"184_CR179","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1083\/jcb.201004082","volume":"190","author":"F Liu","year":"2010","unstructured":"Liu, F. et al. Feedback amplification of fibrosis through matrix stiffening and COX-2 suppression. J. Cell Biol. 190, 693\u2013706 (2010).","journal-title":"J. Cell Biol."},{"key":"184_CR180","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1172\/JCI93561","volume":"128","author":"DJ Tschumperlin","year":"2018","unstructured":"Tschumperlin, D. J., Ligresti, G., Hilscher, M. B. & Shah, V. H. Mechanosensing and fibrosis. J. Clin. Invest. 128, 74\u201384 (2018).","journal-title":"J. Clin. Invest."},{"key":"184_CR181","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02745145 (2018)."},{"key":"184_CR182","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.redox.2016.06.005","volume":"9","author":"A Kurundkar","year":"2016","unstructured":"Kurundkar, A. & Thannickal, V. J. Redox mechanisms in age-related lung fibrosis. Redox Biol. 9, 67\u201376 (2016).","journal-title":"Redox Biol."},{"key":"184_CR183","doi-asserted-by":"crossref","first-page":"eaal3765","DOI":"10.1126\/scitranslmed.aal3765","volume":"9","author":"D Lagares","year":"2017","unstructured":"Lagares, D. et al. Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis. Sci. Transl Med. 9, eaal3765 (2017).","journal-title":"Sci. Transl Med."},{"key":"184_CR184","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/acel.12344","volume":"14","author":"Y Zhu","year":"2015","unstructured":"Zhu, Y. et al. The Achilles\u2019 heel of senescent cells: from transcriptome to senolytic drugs. Aging Cell 14, 644\u2013658 (2015).","journal-title":"Aging Cell"},{"key":"184_CR185","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1002\/art.39061","volume":"67","author":"J Wei","year":"2015","unstructured":"Wei, J. et al. The histone deacetylas sirtuin 1 is reduced in systemic sclerosis and abrogates fibrotic responses by targeting transforming growth factor \u03b2 signaling. Arthritis Rheumatol. 67, 1323\u20131334 (2015).","journal-title":"Arthritis Rheumatol."},{"key":"184_CR186","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1136\/annrheumdis-2014-205740","volume":"75","author":"P Zerr","year":"2016","unstructured":"Zerr, P. et al. Sirt1 regulates canonical TGF-\u03b2 signaling to control fibroblast activation and tissue fibrosis. Ann. Rheum. Dis. 75, 226\u2013233 (2016).","journal-title":"Ann. Rheum. Dis."},{"key":"184_CR187","doi-asserted-by":"crossref","first-page":"69321","DOI":"10.18632\/oncotarget.12504","volume":"7","author":"K Akamata","year":"2016","unstructured":"Akamata, K. et al. SIRT3 is attenuated in systemic sclerosis skin and lungs, and its pharmacologic activation mitigates organ fibrosis. Oncotarget 7, 69321\u201368336 (2016).","journal-title":"Oncotarget"},{"key":"184_CR188","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.cmet.2018.03.016","volume":"27","author":"MG Tarrago","year":"2018","unstructured":"Tarrago, M. G. et al. A potent and specific CD38 inhibitor ameliorates age-related metabolic dysfunction by reversing tissue NAD+ decline. Cell Metab. 27, 1081\u20131095 (2018).","journal-title":"Cell Metab."},{"key":"184_CR189","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.tips.2018.02.001","volume":"39","author":"EN Chini","year":"2018","unstructured":"Chini, E. N. et al. The pharmacology of CD38\/NADase: an emerging target in cancer and diseases of aging. Trends Pharmacol. Sci. 39, 424\u2013436 (2018).","journal-title":"Trends Pharmacol. Sci."},{"key":"184_CR190","doi-asserted-by":"crossref","first-page":"R229","DOI":"10.1186\/ar4070","volume":"14","author":"F Fang","year":"2012","unstructured":"Fang, F. et al. The adipokine adiponectin has potent anti-fibrotic effects mediated via adenosine monophosphate-activated protein kinase: novel target for fibrosis therapy. Arthritis Res. Ther. 14, R229 (2012).","journal-title":"Arthritis Res. Ther."},{"key":"184_CR191","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.3389\/fimmu.2018.01236","volume":"9","author":"F Ursini","year":"2018","unstructured":"Ursini, F. et al. Metformin and autoimmunity: a \u201cnew deal\u201d of an old drug. Front. Immunol. 9, 1236 (2018).","journal-title":"Front. Immunol."},{"key":"184_CR192","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41584-018-0099-0","volume":"14","author":"C Angiolilli","year":"2018","unstructured":"Angiolilli, C. et al. New insights into the genetics and epigenetics of systemic sclerosis. Nat. Rev. Rheumatol. 14, 657\u2013673 (2018).","journal-title":"Nat. Rev. Rheumatol."},{"key":"184_CR193","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jaut.2017.05.004","volume":"83","author":"PS Tsou","year":"2017","unstructured":"Tsou, P. S. & Sawalha, A. H. Unfolding the pathogenesis of scleroderma. J. Autoimmun. 83, 73\u201394 (2017).","journal-title":"J. Autoimmun."},{"key":"184_CR194","doi-asserted-by":"crossref","first-page":"eaaf5307","DOI":"10.1126\/scitranslmed.aaf5307","volume":"10","author":"DK Taylor","year":"2018","unstructured":"Taylor, D. K. et al. T follicular helper-like cells contribute to skin fibrosis. Sci. Transl Med. 10, eaaf5307 (2018).","journal-title":"Sci. Transl Med."},{"key":"184_CR195","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01748084 (2018)."},{"key":"184_CR196","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01086540 (2018)."},{"key":"184_CR197","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01862926 (2017)."},{"key":"184_CR198","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02161406 (2018)."}],"container-title":["Nature Reviews Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41584-019-0184-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-019-0184-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41584-019-0184-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,15]],"date-time":"2024-07-15T01:30:47Z","timestamp":1721007047000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41584-019-0184-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,22]]},"references-count":198,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["184"],"URL":"https:\/\/doi.org\/10.1038\/s41584-019-0184-z","relation":{},"ISSN":["1759-4790","1759-4804"],"issn-type":[{"value":"1759-4790","type":"print"},{"value":"1759-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,22]]},"assertion":[{"value":"22 February 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.R.V. declares that she has acted as a clinical trial investigator for Boehringer-Ingelheim and Genentech\/Roche and is an advisory board member for Boehringer-Ingelheim. J.V. declares that he has acted as a clinical trial investigator for Corbus, Cytori, GlaxoSmithKline and Genentech\/Roche; has received research grants from Bristol-Myers Squibb, Pfizer and the National Institutes of Health (NIH); and is an advisory board member for Boehringer-Ingelheim, Corbus, Emerald, Inventiva and Mitsubishi.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}